Literature DB >> 6587418

Reduced haloperidol in the post-mortem brains of haloperidol-treated patients.

E R Korpi, J E Kleinman, D T Costakos, M Linnoila, R J Wyatt.   

Abstract

We measured the concentrations of haloperidol and its reduced alcohol metabolite in human post-mortem tissues with high-performance/liquid chromatography using electrochemical detection. Both haloperidol and reduced haloperidol were detected and quantified in the occipital cortex of nine schizophrenic patients with a history of haloperidol treatment, but not in six samples from nontreated subjects. Reduced haloperidol concentrations were below the detection limit of the assay in several tissues of rats and mice even after 10 days of haloperidol treatment. The results suggest that reduced haloperidol is present in the brains of haloperidol-treated patients at slightly higher concentrations than haloperidol itself. Further studies are warranted to establish the possible biological importance of this haloperidol metabolite.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6587418     DOI: 10.1016/0165-1781(84)90074-x

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  19 in total

Review 1.  Reduced haloperidol: a factor in determining the therapeutic benefit of haloperidol treatment?

Authors:  W H Chang
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Formation of pyridinium species of haloperidol in human liver and brain.

Authors:  D W Eyles; J J McGrath; S M Pond
Journal:  Psychopharmacology (Berl)       Date:  1996-06       Impact factor: 4.530

3.  Region specific distribution of levomepromazine in the human brain.

Authors:  J Kornhuber; H Weigmann; J Röhrich; J Wiltfang; S Bleich; I Meineke; R Zöchling; S Härtter; P Riederer; C Hiemke
Journal:  J Neural Transm (Vienna)       Date:  2005-07-06       Impact factor: 3.575

Review 4.  Pharmacokinetics of haloperidol: an update.

Authors:  S Kudo; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

5.  Effects of sigma ligands on the cloned mu-, delta- and kappa-opioid receptors co-expressed with G-protein-activated K+ (GIRK) channel in Xenopus oocytes.

Authors:  T Kobayashi; K Ikeda; T Ichikawa; S Togashi; T Kumanishi
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

6.  Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol.

Authors:  J G Shin; K Kane; D A Flockhart
Journal:  Br J Clin Pharmacol       Date:  2001-01       Impact factor: 4.335

7.  Reversible metabolism of haloperidol and reduced haloperidol in Chinese schizophrenic patients.

Authors:  M W Jann; Y W Lam; W H Chang
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

8.  Differences between antipsychotic drugs in persistence of brain levels and behavioral effects.

Authors:  B M Cohen; T Tsuneizumi; R J Baldessarini; A Campbell; S M Babb
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

9.  Synthesis of the enantiomers of reduced haloperidol.

Authors:  J C Jaen; B W Caprathe; S Priebe; L D Wise
Journal:  Pharm Res       Date:  1991-08       Impact factor: 4.200

10.  Quantitative EEG analysis at rest and during photic stimulation in drug-naive patients with first-episode paranoid schizophrenia.

Authors:  Y Wada; Y Takizawa; S Kitazawa; Z Y Jiang; N Yamaguchi
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.